171 related articles for article (PubMed ID: 35557985)
1. LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis.
Mu X; Shen Z; Lin Y; Xiao J; Xia K; Xu C; Chen B; Shi R; Zhu A; Sun X; Tao T; Song X; Xuan Q
Oxid Med Cell Longev; 2022; 2022():8693259. PubMed ID: 35557985
[TBL] [Abstract][Full Text] [Related]
2. Long Noncoding RNA MALAT1 Regulates Cancer Glucose Metabolism by Enhancing mTOR-Mediated Translation of TCF7L2.
Malakar P; Stein I; Saragovi A; Winkler R; Stern-Ginossar N; Berger M; Pikarsky E; Karni R
Cancer Res; 2019 May; 79(10):2480-2493. PubMed ID: 30914432
[TBL] [Abstract][Full Text] [Related]
3. MALAT1 knockdown inhibits prostate cancer progression by regulating miR-140/BIRC6 axis.
Hao T; Wang Z; Yang J; Zhang Y; Shang Y; Sun J
Biomed Pharmacother; 2020 Mar; 123():109666. PubMed ID: 31935634
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
Ma T; Chen H; Wang P; Yang N; Bao J
Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
[No Abstract] [Full Text] [Related]
6. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
7. LncRNA LOXL1-AS1 regulates the tumorigenesis and development of lung adenocarcinoma through sponging miR-423-5p and targeting MYBL2.
Li W; Zhang B; Jia Y; Shi H; Wang H; Guo Q; Li H
Cancer Med; 2020 Jan; 9(2):689-699. PubMed ID: 31758653
[TBL] [Abstract][Full Text] [Related]
8. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
9. Interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 through PI3K/Akt signaling.
He B; Peng F; Li W; Jiang Y
J Cell Biochem; 2019 Mar; 120(3):2908-2918. PubMed ID: 30500989
[TBL] [Abstract][Full Text] [Related]
10. Circular RNA circMBOAT2 promotes prostate cancer progression via a miR-1271-5p/mTOR axis.
Shi J; Liu C; Chen C; Guo K; Tang Z; Luo Y; Chen L; Su Y; Xu K
Aging (Albany NY); 2020 Jul; 12(13):13255-13280. PubMed ID: 32645691
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
Gou L; Zou H; Li B
Cancer Biol Ther; 2019; 20(11):1355-1365. PubMed ID: 31500506
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB.
Tripathi V; Shen Z; Chakraborty A; Giri S; Freier SM; Wu X; Zhang Y; Gorospe M; Prasanth SG; Lal A; Prasanth KV
PLoS Genet; 2013 Mar; 9(3):e1003368. PubMed ID: 23555285
[TBL] [Abstract][Full Text] [Related]
13. NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and MALAT1 through STAT3 and E2F1.
Jing Z; Liu Q; Xie W; Wei Y; Liu J; Zhang Y; Zuo W; Lu S; Zhu Q; Liu P
Cell Signal; 2022 Apr; 92():110265. PubMed ID: 35085770
[TBL] [Abstract][Full Text] [Related]
14. Silencing of lncRNA MALAT1 inhibits cell cycle progression via androgen receptor signaling in prostate cancer cells.
Dai X; Liu L; Liang Z; Guo K; Xu S; Wang H
Pathol Res Pract; 2019 Apr; 215(4):712-721. PubMed ID: 30642743
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
16. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-183 affects the development of gastric cancer by regulating autophagy via MALAT1-miR-183-SIRT1 axis and PI3K/AKT/mTOR signals.
Li H; He C; Wang X; Wang H; Nan G; Fang L
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3163-3171. PubMed ID: 31352788
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of long non-coding RNA MALAT1 elevates microRNA-429 to suppress the progression of hypopharyngeal squamous cell carcinoma by reducing ZEB1.
Liu X; Zhao W; Wang X
Life Sci; 2020 Dec; 262():118480. PubMed ID: 32980391
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family.
Li ZB; Chu HT; Jia M; Li L
Biochem Biophys Res Commun; 2020 May; 525(3):581-588. PubMed ID: 32115147
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR‑34a/cyclin D1 axis.
Duan G; Zhang C; Xu C; Xu C; Zhang L; Zhang Y
Int J Oncol; 2019 Jan; 54(1):17-28. PubMed ID: 30365098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
